Emerging Biopharma

Develop and execute a winning asset launch strategy

For emerging biopharma and biotech companies to excel in today’s challenging environment, it’s critical to leverage a deep understanding of the patient profile and market dynamics throughout the journey from clinical to commercial.IQVIA Asset Maximizeris a comprehensive suite of solutions, delivered by experts dedicated to you, to help your breakthroughs get to patients, faster.

对于需要确保临床试验设计的制药公司，资产成功开始了，考虑了对监管机构，付款人，处方者和患者的价值的终点。传达该价值需要一种适应性的全渠道方法，以激活和吸引所有利益相关者在启动和整个产品生命周期中。与伊克维亚（Iqvia）合作，临床发展的全球领导者，现实世界证据以及新疗法的商业化，以在发射及其他地区提供获胜的资产。